Ting Luo

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Randomized Controlled Trial

Positive Breast Cancer

Top Venues

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Lan Chen, Xi Yan, Ting Luo, Tinglun Tian, Ping He, Xiaorong Zhong
Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes. Cancer medicine 13 (10) (2024)
Lan Chen, Xi Yan, Ting Luo, Tinglun Tian, Ping He, Xiaorong Zhong
Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes. Cancer medicine 13 (10) (2024)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Daoli Ye, Zhao Xudong, Qingfeng Wang, Hongfeng Gou, Ting Luo
Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open 13 (4) (2023)
Qiancheng Hu, Wenli Kang, Qingfeng Wang, Ting Luo
Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. BMJ open 12 (5) (2022)